Pharm Final NU 553 Exam Questions With
Correct Answers
An |Investigational |New |Drug |is |filed |with |the |U.S. |Food |and |Drug |Administration:
Prior |to |human |testing |of |any |new |drug |entity
3 |multiple |choice |options
Phase |IV |clinical |trials |in |the |United |States |are |also |known |as:
Post |marketing |research
3 |multiple |choice |options
Off-label |prescribing |is:
Legal |if |there |is |scientific |evidence |for |the |use
3 |multiple |choice |options
Rifampin |is |a |nonspecific |CYP450 |inducer |that |may:
Induce |the |metabolism |of |drugs, |such |as |oral |contraceptives, |leading |to |therapeutic |failure
,You |are |going |to |prescribe |a |drug |and |the |electronic |health |record |(EHR) |alerts |you |that |there |
is |apotential |drug-drug |interaction. |The |alert |is |generated |by:
The |EHR |clinical |decision |support |system
Pharmacoeconomics |is:
The |analysis |of |the |costs |and |consequences |of |any |health-care-related |treatment |or |service
The |direct |costs |of |drug |therapy |include:
Pain |and |suffering |due |to |inadequate |drug |therapy
Indirect |costs |associated |with |drug |therapy |include:
Loss |of |wages |while |undergoing |drug |therapy
The |intangible |costs |of |drug |therapy |include:
inconvience |pain |and |suffering |incurred |with |therapy
When |a |pharmacoeconomic |analysis |looks |at |two |or |more |treatment |alternatives |that |are |
consideredequal |in |efficacy |and |compares |the |costs |of |each |it |is |referred |to |as:
Cost-minimization |analysis
,Cost-effectiveness |analysis |compares |two |or |more |treatments |or |programs |that |are:
Not |necessarily |therapeutically |equivalent
When |the |costs |of |a |specific |treatment |or |intervention |are |calculated |and |then |compared |
withthe |dollar |value |of |the |benefit |received |it |is |referred |to |as:
Cost-benefit |analysis
A |prescription |needs |to |be |written |for:
Legend |drugs; |most |controlled |drugs; |and |medical |devices
Drugs |that |have |a |significant |first-pass |effect:
Are |rapidly |metabolized |by |the |liver |and |may |have |little |if |any |desired |action
Drugs |that |are |receptor |agonists |may |demonstrate |what |property?
Desensitization |or |downregulation |with |continuous |use
, Which |of |the |following |drug |classes |is |associated |with |significant |differences |in |metabolism |
basedon |gender?
Serotonin |reuptake |inhibitors
Since |40% |of |bone |accrual |occurs |during |adolescence, |building |bone |during |this |time |is |
critical.Ways |to |improve |bone |accrual |in |adolescents |include:
Encouraging |a |daily |dietary |intake |of |1,300 |mg |of |calcium |and |400 |IU |of |vitaminD
Premenstrual |dysphoric |disorder |(PMDD) |occurs |in |a |fairly |small |number |of |patients. |Theories |
of |the |pathology |behind |PMDD |that |are |supported |in |research |include:
Altered |sensitivity |in |the |serontonic |system
The |goal |of |testosterone |replacement |therapy |is
Testosterone |levels |in |the |mid-normal |range |1 |week |after |an |injection
Men |who |are |prescribed |phosphodiesterase |type |5 |(PDE-5) |inhibitors |for |erectile |dysfunction |
should |be |educated |regarding |the |adverse |effects |of |the |drug |which |include
hearing |loss
Correct Answers
An |Investigational |New |Drug |is |filed |with |the |U.S. |Food |and |Drug |Administration:
Prior |to |human |testing |of |any |new |drug |entity
3 |multiple |choice |options
Phase |IV |clinical |trials |in |the |United |States |are |also |known |as:
Post |marketing |research
3 |multiple |choice |options
Off-label |prescribing |is:
Legal |if |there |is |scientific |evidence |for |the |use
3 |multiple |choice |options
Rifampin |is |a |nonspecific |CYP450 |inducer |that |may:
Induce |the |metabolism |of |drugs, |such |as |oral |contraceptives, |leading |to |therapeutic |failure
,You |are |going |to |prescribe |a |drug |and |the |electronic |health |record |(EHR) |alerts |you |that |there |
is |apotential |drug-drug |interaction. |The |alert |is |generated |by:
The |EHR |clinical |decision |support |system
Pharmacoeconomics |is:
The |analysis |of |the |costs |and |consequences |of |any |health-care-related |treatment |or |service
The |direct |costs |of |drug |therapy |include:
Pain |and |suffering |due |to |inadequate |drug |therapy
Indirect |costs |associated |with |drug |therapy |include:
Loss |of |wages |while |undergoing |drug |therapy
The |intangible |costs |of |drug |therapy |include:
inconvience |pain |and |suffering |incurred |with |therapy
When |a |pharmacoeconomic |analysis |looks |at |two |or |more |treatment |alternatives |that |are |
consideredequal |in |efficacy |and |compares |the |costs |of |each |it |is |referred |to |as:
Cost-minimization |analysis
,Cost-effectiveness |analysis |compares |two |or |more |treatments |or |programs |that |are:
Not |necessarily |therapeutically |equivalent
When |the |costs |of |a |specific |treatment |or |intervention |are |calculated |and |then |compared |
withthe |dollar |value |of |the |benefit |received |it |is |referred |to |as:
Cost-benefit |analysis
A |prescription |needs |to |be |written |for:
Legend |drugs; |most |controlled |drugs; |and |medical |devices
Drugs |that |have |a |significant |first-pass |effect:
Are |rapidly |metabolized |by |the |liver |and |may |have |little |if |any |desired |action
Drugs |that |are |receptor |agonists |may |demonstrate |what |property?
Desensitization |or |downregulation |with |continuous |use
, Which |of |the |following |drug |classes |is |associated |with |significant |differences |in |metabolism |
basedon |gender?
Serotonin |reuptake |inhibitors
Since |40% |of |bone |accrual |occurs |during |adolescence, |building |bone |during |this |time |is |
critical.Ways |to |improve |bone |accrual |in |adolescents |include:
Encouraging |a |daily |dietary |intake |of |1,300 |mg |of |calcium |and |400 |IU |of |vitaminD
Premenstrual |dysphoric |disorder |(PMDD) |occurs |in |a |fairly |small |number |of |patients. |Theories |
of |the |pathology |behind |PMDD |that |are |supported |in |research |include:
Altered |sensitivity |in |the |serontonic |system
The |goal |of |testosterone |replacement |therapy |is
Testosterone |levels |in |the |mid-normal |range |1 |week |after |an |injection
Men |who |are |prescribed |phosphodiesterase |type |5 |(PDE-5) |inhibitors |for |erectile |dysfunction |
should |be |educated |regarding |the |adverse |effects |of |the |drug |which |include
hearing |loss
